ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
19.94
-0.39 (-1.92%)
At close: Jun 5, 2025, 4:00 PM
19.96
+0.02 (0.10%)
After-hours: Jun 5, 2025, 4:37 PM EDT
ADMA Biologics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for ADMA Biologics stock ranges from a low of $14 to a high of $32. The average analyst price target of $24.25 forecasts a 21.61% increase in the stock price over the next year.
Price Target: $24.25 (+21.61%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADMA Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy Maintains $25 → $32 | Strong Buy | Maintains | $25 → $32 | +60.48% | May 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +25.38% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $26 | Strong Buy | Maintains | $18 → $26 | +30.39% | Nov 8, 2024 |
| Raymond James | Raymond James | Strong Buy Maintains $18 → $25 | Strong Buy | Maintains | $18 → $25 | +25.38% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | -9.73% | Oct 14, 2024 |
Financial Forecast
Revenue This Year
518.16M
from 426.45M
Increased by 21.50%
Revenue Next Year
656.95M
from 518.16M
Increased by 26.79%
EPS This Year
0.67
from 0.81
Decreased by -16.89%
EPS Next Year
0.99
from 0.67
Increased by 47.47%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 551.9M | 717.2M | 953.5M | ||
| Avg | 518.2M | 657.0M | 830.0M | ||
| Low | 482.8M | 595.8M | 724.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 29.4% | 38.4% | 45.1% | ||
| Avg | 21.5% | 26.8% | 26.3% | ||
| Low | 13.2% | 15.0% | 10.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.77 | 1.12 | 1.40 | ||
| Avg | 0.67 | 0.99 | 1.28 | ||
| Low | 0.60 | 0.88 | 1.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.4% | 66.9% | 40.7% | ||
| Avg | -16.9% | 47.5% | 29.1% | ||
| Low | -26.2% | 31.0% | 12.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.